SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Definitive Healthcare Corp. (DH) has a negative trailing P/E of -0.7, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 6.0 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -138.58%, forward earnings yield 16.58%. PEG 0.56 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (100/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (0.56); analyst target implies upside (+209.9%).
- Forward P/E 6.0 — analysts expect a return to profitability with estimated EPS of $0.17 for FY2026.
- PEG Ratio 0.56 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield -138.58% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 16.58% as earnings recover.
- Analyst consensus target $3.13 (+209.9% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 42/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — DH
Valuation Multiples
P/E (TTM)-0.7
Forward P/E6.0
PEG Ratio0.56
Forward PEG0.56
P/B Ratio0.36
P/S Ratio0.42
EV/EBITDA-0.8
Per Share Data
EPS (TTM)$-1.34
Forward EPS (Est.)$0.17
Book Value / Share$3.67
Revenue / Share$2.34
FCF / Share$0.46
Yields & Fair Value
Earnings Yield-138.58%
Forward Earnings Yield16.58%
Dividend Yield0.00%
SharesGrow IV$11.03 (+992.1%)
Analyst Target$3.13 (+209.9%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2019 |
-177.3 |
0.00 |
5.31 |
75.49 |
0.11% |
| 2020 |
-79.9 |
-0.66 |
3.51 |
35.50 |
0.07% |
| 2021 |
-51.1 |
0.80 |
3.04 |
15.96 |
0.31% |
| 2022 |
-153.9 |
2.47 |
1.17 |
4.99 |
1.16% |
| 2023 |
-5.5 |
0.00 |
1.30 |
4.46 |
1.10% |
| 2024 |
-1.2 |
-0.01 |
1.08 |
1.90 |
1.07% |
| 2025 |
-2.2 |
0.03 |
1.09 |
1.27 |
1.03% |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2019 |
$-0.24 |
$85.5M |
$-36.4M |
-42.6% |
| 2020 |
$-0.90 |
$118.32M |
$-87.65M |
-74.1% |
| 2021 |
$-0.63 |
$166.15M |
$-61.26M |
-36.9% |
| 2022 |
$-0.22 |
$222.65M |
$-22.26M |
-10% |
| 2023 |
$-1.79 |
$251.42M |
$-202.39M |
-80.5% |
| 2024 |
$-3.54 |
$252.2M |
$-413.12M |
-163.8% |
| 2025 |
$-1.30 |
$241.52M |
$-138.93M |
-57.5% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$0.17 |
$0.16 – $0.17 |
$223.61M |
$221.56M – $225.89M |
7 |
| 2027 |
$0.19 |
$0.16 – $0.23 |
$224.28M |
$219.65M – $230.79M |
6 |
| 2028 |
$0.21 |
$0.20 – $0.21 |
$241.07M |
$241.07M – $241.07M |
3 |
